Nyhetsflöde

Regulatoriska pressmeddelanden

Icke regulatoriska pressmeddelanden och nyheter

2 december 2021

According to Reports and Data the epinephrine (more commonly known as adrenaline) market size today exceed USD 2 bi… https://t.co/cOt51tdBF6

2 december 2021

NEWS: Orexo to develop a nasal adrenaline medication based on the amorphOX platform. Adrenaline is commonly used fo… https://t.co/EVN5iCbIm5

1 december 2021

Our CEO Nikolaj Sørensen in @Redeye_ "Hot Seat". A fireside chat focusing on the company´s digital therapeutic vent… https://t.co/hB4pEVn7Jb

Europa

USA

Lena Wange

IR & Corporate Communications Director

Växel: +46 (0)18 780 88 00

Direktnummer: +46 73 064 16 36

Email: ir@orexo.com

Plats: Uppsala, Sverige

Dennis Urbaniak

EVP Digital Therapeutics

Växel: +1 (0)855 982 7658

Direktnummer: +1 973 294 3183

Email: us.media@orexo.com

Plats: New Jersey, USA